全文获取类型
收费全文 | 1791篇 |
免费 | 163篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 85篇 |
妇产科学 | 33篇 |
基础医学 | 263篇 |
口腔科学 | 22篇 |
临床医学 | 234篇 |
内科学 | 368篇 |
皮肤病学 | 26篇 |
神经病学 | 210篇 |
特种医学 | 186篇 |
外科学 | 162篇 |
综合类 | 35篇 |
一般理论 | 6篇 |
预防医学 | 158篇 |
眼科学 | 12篇 |
药学 | 97篇 |
中国医学 | 2篇 |
肿瘤学 | 53篇 |
出版年
2023年 | 13篇 |
2021年 | 29篇 |
2020年 | 23篇 |
2019年 | 22篇 |
2018年 | 25篇 |
2017年 | 20篇 |
2016年 | 24篇 |
2015年 | 43篇 |
2014年 | 41篇 |
2013年 | 48篇 |
2012年 | 43篇 |
2011年 | 66篇 |
2010年 | 51篇 |
2009年 | 31篇 |
2008年 | 60篇 |
2007年 | 73篇 |
2006年 | 63篇 |
2005年 | 55篇 |
2004年 | 49篇 |
2003年 | 55篇 |
2002年 | 51篇 |
2001年 | 51篇 |
2000年 | 44篇 |
1999年 | 41篇 |
1998年 | 48篇 |
1997年 | 38篇 |
1996年 | 44篇 |
1995年 | 44篇 |
1994年 | 26篇 |
1993年 | 29篇 |
1992年 | 27篇 |
1991年 | 50篇 |
1990年 | 38篇 |
1989年 | 34篇 |
1988年 | 42篇 |
1987年 | 41篇 |
1986年 | 30篇 |
1985年 | 44篇 |
1984年 | 29篇 |
1983年 | 25篇 |
1982年 | 35篇 |
1981年 | 26篇 |
1980年 | 34篇 |
1979年 | 17篇 |
1978年 | 19篇 |
1977年 | 22篇 |
1976年 | 16篇 |
1975年 | 16篇 |
1974年 | 15篇 |
1968年 | 11篇 |
排序方式: 共有1964条查询结果,搜索用时 0 毫秒
31.
Alison Rusnak Shawna Morrison Erika Smith Valerie Hastings Kelly Anderson Caitlin Aldridge Sari Zelenietz Karen Reddick Sonia Regnier Ellen Alie Nayaar Islam Rutaaba Fasih Susan Peddle Erin Cordeiro Eva Tomiak Jean M. Seely 《Current oncology (Toronto, Ont.)》2022,29(11):8742
Breast tissue density (BTD) is known to increase the risk of breast cancer but is not routinely used in the risk assessment of the population-based High-Risk Ontario Breast Screening Program (HROBSP). This prospective, IRB-approved study assessed the feasibility and impact of incorporating breast tissue density (BTD) into the risk assessment of women referred to HROBSP who were not genetic mutation carriers. All consecutive women aged 40–69 years who met criteria for HROBSP assessment and referred to Genetics from 1 December 2020 to 31 July 2021 had their lifetime risk calculated with and without BTD using Tyrer-Cuzick model version 8 (IBISv8) to gauge overall impact. McNemar’s test was performed to compare eligibility with and without density. 140 women were referred, and 1 was excluded (BRCA gene mutation carrier and automatically eligible). Eight of 139 (5.8%) never had a mammogram, while 17/131 (13%) did not have BTD reported on their mammogram and required radiologist review. Of 131 patients, 22 (16.8%) were clinically impacted by incorporation of BTD: 9/131 (6.9%) became eligible for HROBSP, while 13/131 (9.9%) became ineligible (p = 0.394). It was feasible for the Genetics clinic to incorporate BTD for better risk stratification of eligible women. This did not significantly impact the number of eligible women while optimizing the use of high-risk supplemental MRI screening. 相似文献
32.
33.
Induction of proliferation of B prolymphocytic leukemia cells by phorbol ester and native or recombinant interferon-gamma 总被引:1,自引:0,他引:1
Phorbol ester phorbol myristate acetate (PMA) induces proliferation in nonmalignant human B cells and B cells from a patient with B prolymphocytic leukemia (B-PLL). Mitogen-free T cell-derived conditioned medium acts synergistically with PMA in inducing proliferation of B-PLL cells but does not enhance the PMA-stimulated outgrowth of nonmalignant B cells. Interleukin 2 (IL-2) has no effect on the outgrowth of B-PLL cells, and monoclonal antibodies against the IL-2 receptor do not influence the response to PMA and conditioned medium. Recombinant interferon-gamma (IFN-gamma), in contrast, is a potent enhancer of PMA-induced proliferation of B-PLL cells. With gel filtration techniques and with the use of anti-IFN-gamma antibodies, it is shown that IFN-gamma in the conditioned medium is responsible for the observed increase in B-PLL cell proliferation. Preincubation of B- PLL cells with IFN-gamma induces responsiveness to PMA, whereas IFN- gamma alone had no effect on these cells when pretreated with PMA. The combined data show that, in the presence of PMA, native and recombinant IFN-gamma are growth factors for B cells from a B-PLL patient and that IL-2 is not involved in this process. 相似文献
34.
Male (NZW x BXSB)F1 (W/BF1) mice develop systemic autoimmunity involving autoantibodies, progressive thrombocytopenia, lupus nephritis, and degenerative coronary vascular disease with myocardial infarction. Platelet-associated IgG (PAIgG) on the platelet surface mediates platelet destruction by the reticuloendothelial system in the autoimmune thrombocytopenic purpura (ATP) of W/BF1 mice. Because the epitopes targeted in ATP by PAIgG have not been identifiable using serum from thrombocytopenic W/BF1 mice, we developed seven hybridomas secreting antiplatelet monoclonal antibodies (MoAbs) using splenocytes of thrombocytopenic W/BF1 mice. Epitopes recognized by three MoAbs were similar to those recognized by PAIgG, because eluted IgG from platelets of thrombocytopenic W/BF1 mice inhibited platelet binding by MoAbs in competitive micro-enzyme-linked immunosorbent assay. Hybridoma cells or purified Ig from the ascites of two clones (2A12 and 6A6), when injected into nude mice produced acute thrombocytopenia, elevated the levels of PAIgG, purpura, and megakaryocytosis. MoAbs of two clones also reacted with single-stranded DNA or double-stranded DNA, and one of these clones (4-13) bound to cardiolipin (CL) but was nonpathogenic in nude mice, suggesting that anti-CL and antiplatelet autoantibodies can be distinct. On immunoblotting analysis, antiplatelet MoAbs frequently bound a 100-Kd platelet protein. These MoAbs contribute to an understanding of the etiopathogenesis of ATP and the several antigens and autoantibodies involved. 相似文献
35.
Long‐term outcomes with first‐ vs. second‐generation drug‐eluting stents in saphenous vein graft lesions 下载免费PDF全文
Nagendra R. Pokala BS Rohan V. Menon BS Siddharth M. Patel BS George Christopoulos MD Georgios E. Christakopoulos MD Anna P. Kotsia MD Bavana V. Rangan BDS MPH Michele Roesle RN Shuaib Abdullah MD Jerrold Grodin MD Dharam J. Kumbhani MD SM MRCP Jeffrey Hastings MD Subhash Banerjee MD Emmanouil S. Brilakis MD PhD 《Catheterization and cardiovascular interventions》2016,87(1):34-40
36.
37.
Two experiments investigated the effect of electroconvulsive shock on the performance of a one-way active avoidance response. In the first experiment it was found that if the response was learned under scopolamine, ECS given prior to relearning failed to produce a deficit. The second experiment demonstrated that ECS facilitated relearning of a response trained to a low criterion level while it disrupted performance of a response trained to a strict criterion. These results support other indications that Deutsch's memory model has predictive value for proactive effects of ECS on relearning (retrieval). 相似文献
38.
Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. 总被引:3,自引:1,他引:3 下载免费PDF全文
39.
Membrane expression of platelet calpain 总被引:1,自引:1,他引:1
Platelet calpain has many platelet substrates, including external membrane proteins. We thus investigated whether platelet calpain II was associated with platelet membranes in unstimulated and thrombin- activated platelets. A monospecific, goat polyclonal antibody was reared to purified platelet calpain II. Sixteen whole platelet lysates were found to contain 4.5 +/- 0.7 micrograms calpain antigen II per 10(8) platelets (mean +/- SEM) as determined by a competitive enzyme- linked immunosorbent assay. Using the dipeptide fluorogenic substrate, Suc-Leu-Tyr-MCA, 17 human platelet lysates contained 3.6 +/- 0.4 micrograms calpain activity per 10(8) platelets. Platelet calpain II was associated with the Triton X-100 insoluble platelet cytoskeletons from both unstimulated and thrombin-activated platelets. When compared with the total cell content of platelet calpain II, calpain antigen (10% to 13%) and calpain activity (24% to 28%) was associated with platelet cytoskeletons in unstimulated and thrombin-activated platelets, respectively. On immunoblot, the heavy chain (80 Kd) of calpain II was detected in platelet cytoskeletons. Subcellular fractionation studies on both unstimulated and thrombin-activated platelets, revealed that half of the total platelet calpain II antigen was associated with cytosol, and the other half was associated with the membrane fraction. Platelet calpain II was not seen on the surface of unstimulated, paraformaldehyde fixed platelets by immunofluorescence. However, on thrombin-activated platelets, rim immunofluorescence was seen, indicating that activated platelets externalize their calpain. This observation was confirmed by the finding that about 2,000 molecules per platelet of an 125I-anti-calpain II Fab' specifically bound to thrombin-activated but not unstimulated platelets. Both dibucaine (1 mmol/L) and platelet activating factor (1.86 mumol/L) in the absence of external Ca++, but not collagen (5 micrograms/mL) or ionophore A23187 (2.5 mumol/L) in the absence of external Ca++, were also able to externalize platelet calpain II antigen, as indicated by a similar level of specific 125I-anti-calpain II Fab'-platelet binding. These combined studies indicate that platelet calpain II is a major protein, comprising 2% of total platelet protein, a substantial portion of which is membrane-associated. When platelets are activated by thrombin and platelet activating factor, calpain II antigen also becomes present on the external platelet surface. 相似文献
40.
Phillip E. Posch Alice E. Hastings Sandra Rosen-Bronson John R. Richert Carolyn Katovich Hurley 《European journal of immunology》1996,26(8):1884-1891
Definition of peptide binding motifs for DR molecules has proven difficult as the peptides that bind to a DR molecule have shown extensive variability at putative motif positions. Recent studies suggest that specific peptide anchor residues (motif positions) and specific DR residues can differ in importance for peptide binding to a DR molecule. To assess further the relevance of individual peptide anchor residues, the binding of serial alanine-substituted analogs of influenza virus hemagglutinin (HA) 306–318 and human myelin basic protein (MBP) 152–165 to a panel of transfected wild-type DR molecules was examined. This analysis included DR molecules from a wide range of allelic families and, unlike most earlier studies, multiple members of single DR allelic families. The data show that different peptide residues serve as critical anchors for binding to different DR molecules. For example, MBP binding to DR(α,β1*0303) required peptide residues F154 (i), R159 (i + 5) and R162 (i + 8). In contrast, MBP binding to DR(α,β1*0102) required peptide residues I153 (i) and L156 (i + 3). More importantly, the combination of critical anchor residues in HA and MBP differed for binding to a single DR molecule [e.g. V309 (i) for HA and I153 (i) and L156 (i + 3) for MBP binding to DR(α,β1*0102)]. Although the location of the binding pocket in each DR molecule compared to the DR (α,β1*0101) crystal is expected to be similar and suggests a common extended DR binding motif, the present results suggest that the relative importance of individual peptide anchor residues and of the corresponding DR binding pockets will differ for each DR/peptide complex. 相似文献